TCGA's Ovarian Cancer Study Points to Range of PGx Strategies, Potential Role for PARP Inhibitors
June 29, 2011
TCGA's Ovarian Cancer Study Points to Range of PGx Strategies, Potential Role for PARP Inhibitors
The TCGA team identified 68 genes that could be targeted by existing drugs or experimental compounds, and singled out PARP inhibitors as a drug class with particular potential. The study also provides a potential basis for subtype-based diagnostics to stratify patients according to their cancer's genomic variation.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- GenomeWeb Feature: The Rise of Lung Cancer Genetic Testing
May 8, 2013 / Pharmacogenomics Reporter - TCGA Study Provides 'Roadmap' for Targeted Therapy, Genomic Subtyping in Ovarian Cancer
June 29, 2011 / Clinical Sequencing News - Multi-institutional GWAS IDs Variant to Improve Warfarin Dosing in People of African Descent
June 12, 2013 / Pharmacogenomics Reporter - TCGA Study Shows Molecular Subtypes May Better Stratify Endometrial Cancer Patients than Histology
May 1, 2013 / Pharmacogenomics Reporter - Prostate Cancer Risk Markers Show Promise for Test to ID Elevated Risk in Men with Benign Hyperplasia
April 3, 2013 / Pharmacogenomics Reporter